SGMT vs. YMAB

In the year-to-date period, SGMT achieves a -8.67% return, which is significantly lower than YMAB's 21.41% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Sagimet Biosciences Inc. (SGMT) and Y-mAbs Therapeutics, Inc. (YMAB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current SGMT Sharpe Ratio is -0.04, which is lower than the YMAB Sharpe Ratio of 0.48. The chart below compares the historical Sharpe Ratios of SGMT and YMAB, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither SGMT nor YMAB has paid dividends to shareholders.

The maximum SGMT drawdown since its inception was -86.59%, smaller than the maximum YMAB drawdown of -94.78%. Use the drawdown chart below to compare losses from any high point for SGMT and YMAB. For additional features, visit the drawdowns tool.

Sagimet Biosciences Inc. (SGMT) has a higher volatility of 37.26% compared to Y-mAbs Therapeutics, Inc. (YMAB) at 20.26%. This indicates that SGMT's price experiences larger fluctuations and is considered to be riskier than YMAB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Sagimet Biosciences Inc. and Y-mAbs Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.